SP2509

SP2509 is a small molecule inhibitor targeting lysine-specific demethylase 1 (LSD1/KDM1A), functioning as a selective and potent antagonist of LSD1's enzymatic activity and protein interactions. It exhibits significant antitumor activity in multiple cancer types, including retinoblastoma, renal carcinoma, and prostate cancer, by inducing cell cycle arrest at the G0/G1 phase, promoting apoptosis, and downregulating antiapoptotic factors like Bcl-2 and Mcl-1. SP2509 has also demonstrated inhibitory activity against the JAK/STAT3 signaling pathway, attributed to LSD1 inhibition, and can disrupt protein-protein interactions with epigenetic complexes such as CoREST and specific transcription factors (e.g., TBX2), affecting downstream oncogenic and resistance mechanisms. Preclinical studies suggest that SP2509 may also reduce viral replication in HSV-1 infection and modulate epigenetic regulation impacting organelle homeostasis. SP2509 is developed primarily as an anticancer agent and may hold potential for combination therapy with chemotherapeutic drugs.